切换至 "中华医学电子期刊资源库"

中华腔镜泌尿外科杂志(电子版) ›› 2018, Vol. 12 ›› Issue (05) : 352 -355. doi: 10.3877/cma.j.issn.1674-3253.2018.05.015

所属专题: 文献

实验研究

表达甲酰辅酶A转移酶的大肠杆菌对大鼠尿草酸浓度的影响
赖德辉1,(), 李名钊2, 盛明1, 李逊1, 何永忠1, 李天1, 徐桂彬1, 杨炜青1   
  1. 1. 510700 广州医科大学附属第五医院泌尿外科;510700 广州医科大学附属第五医院微创新技术和产品转化中心
    2. 510630 广州,中山大学附属第三医院泌尿外科
  • 收稿日期:2018-01-04 出版日期:2018-10-01
  • 通信作者: 赖德辉
  • 基金资助:
    广州医科大学博士启动项目(2014C40)

Probiotic administration of Escherichia coli Nissle 1917 with FCoAT expression reduces urinary oxalate in rat model

Dehui Lai1,(), Mingzhao Li2, Xun Li1, Yongzhong HE1, Tian Li1, Guibin Xu1, Weiqing Yang1   

  1. 1. Department of Urology, the Fifth Affiliated Hospital, Guangzhou Medical University, Guangzhou 510700, China; Minimally Invasive Technique and Product Translational Center, Guangzhou Medical University, Guangzhou 510700, China
    2. Department of Urology, the Third Affiliated Hospital, Sun Yat-sen University, Guangzhou 510630, China
  • Received:2018-01-04 Published:2018-10-01
  • Corresponding author: Dehui Lai
  • About author:
    Corresponding Author: Dehui Lai, Email:
引用本文:

赖德辉, 李名钊, 盛明, 李逊, 何永忠, 李天, 徐桂彬, 杨炜青. 表达甲酰辅酶A转移酶的大肠杆菌对大鼠尿草酸浓度的影响[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2018, 12(05): 352-355.

Dehui Lai, Mingzhao Li, Xun Li, Yongzhong HE, Tian Li, Guibin Xu, Weiqing Yang. Probiotic administration of Escherichia coli Nissle 1917 with FCoAT expression reduces urinary oxalate in rat model[J/OL]. Chinese Journal of Endourology(Electronic Edition), 2018, 12(05): 352-355.

目的

探讨喂饲表达甲酰辅酶A转移酶(FCoAT)的大肠杆菌Nissle1917(EcN-Frc)对大鼠尿草酸浓度的影响。

方法

将30只雄性SD大鼠随机分为六组(编号A-F),每组5只。除A组外,其余五组在食物中每克添加1%草酸。B组每次喂食前30 min,喂食1 ml EcN-Frc培养液,C、D、E、F组喂食1 ml EcN-Frc悬液(活细菌数103)。C、D、E、F组喂饲细菌的方式分别为每日1次,每3 d一次,每周一次和观察期内首日喂养一次。实验周期为2周,分别于喂养当日,喂养后3、6、9、14 d分别记录大鼠健康情况和24 h尿草酸排泄量。

结果

口服ECN-Frc能有效减低高草酸饮食大鼠的24 h尿草酸排泄量。含103活菌数的EcN-Frc在喂养后3 d即可发挥作用。1次喂服103个活菌数的ECN-Frc,2周后仍能有效降低大鼠尿中草酸浓度。所有大鼠观察期内均体健,未见明显异常。

结论

低剂量口服EcN-Frc能有效降低高草酸饮食大鼠的24 h尿草酸排泄量,且安全,耐受性好。

Objective

To study of using E.coli Nissle1917 which can express FCoAT (EcN-Frc) as probiotic treatment to reduce urine oxalate in a rat model.

Methods

Thirty male SD rats were randomly divided into 6 groups (A to F). 1% oxalate was added to the diet for rats in group B, C, D, E, F; while rats in group A received regular diet. Furthermore, 30 minutes before each feeding, each rats in group B received 1 ml suspension, while those in group C, D, E, F was given 1 ml EcN-Frc suspension (103 viable bacteria). Rats in group C, D, E, F were feeding bacteria every day, once every three days, once a week, respectively. 24-hour urine specimens were obtained on days 0, 3, 6, 9, 14 by placing the rats in metabolic cages.

Results

Hyperoxaluria rats due to high dietary oxalate were treated by EcN-Frc. It can effectively reduce the high urinary oxalate level in rat model since day 3 after supplementation. The effect of the decrease proved directly proportional to the dose of EcN-Frc.But, one dose of EcN-Frc (103 viable bacteria) can still effectively reduce urinary oxalate in a 2 weeks period. It showed that EcN-Frc had the ability to stay stable in rat’s intestine and grew well. In addition, during 2 weeks period, all rats kept health with no signs of toxicity.

Conclusions

Probiotic administration of low dose EcN-Frc can effectively reduce the high urinary oxalate in hyperoxaluria rats. EcN-Frc can stay stable in rat’s intestine and play a role in degrading oxalate. This approach appears to be safe and good tolerance.

表1 喂饲EcN-Frc对高草酸尿大鼠24 h尿草酸排泄的影响[±s(min-max)]
表2 喂饲EcN-Frc对高草酸尿大鼠平均体重的影响[±s(min-max)]
[1]
赖德辉,李逊,雷鸣, 等. 克隆与表达产甲酸草酸杆菌代谢基因Frc及临床意义[J]. 中华腔镜泌尿外科杂志(电子版), 2010, 4(3):239-244.
[2]
赖德辉,李逊,雷鸣, 等. 基因工程构建表达融合蛋白GST-FCoAT的益生大肠杆菌EcN-Frc[J]. 实用医学杂志, 2010, 26(24):4480-4482.
[3]
Sidhu H, Schmidt ME, Cornelius JG, et al. Direct correlation between hyperoxaluria/oxalate stone disease and the absence of the gastrointestinal tract-dwelling bacterium Oxalobacter formigenes:possible prevention by gut recolonization or enzyme replacement therapy[J]. J Am Soc Nephrol, 1999, 10 Suppl 14:S334-40.
[4]
Sidhu H, Allison MJ, Chow JM, et al. Rapid reversal of hyperoxaluria in a rat model after probiotic administration of Oxalobacter formigenes[J]. J Urol, 2001, 166(4):1487-1491.
[5]
Hatch M, Cornelius J, Allison M, et al. Oxalobacter sp. Reduces urinary oxalate excretion by promoting enteric oxalate secretion[J]. Kidney Int, 2006, 69(4):691-698.
[6]
Hoppe B, Beck B, Gatter N, et al. Oxalobacter formigenes: a potential tool for the treatment of primary hyperoxaluria type 1[J]. Kidney Int, 2006, 70(7):1305-1311.
[7]
Dobrindt U, Hochhut B, Hentschel U, et al. Genomic islands in pathogenic and environmental microorganisms[J]. Nat Rev Microbiol, 2004, 2(5):414-424.
[8]
Grozdanov L, Zähringer U, Blum-Oehler G, et al. A single nucleotide exchange in the wzy gene is responsible for the semirough O6 lipopolysaccharide phenotype and serum sensitivity of Escherichia coli strain Nissle 1917[J]. J Bacteriol, 2002, 184(21):5912-5925.
[9]
Sun J, Gunzer F, Westendorf AM, et al. Genomic peculiarity of coding sequences and metabolic potential of probiotic Escherichia coli strain Nissle 1917 inferred from raw genome data[J]. J Biotechnol, 2005, 117(2):147-161.
[10]
Grozdanov L, Raasch C, Schulze J, et al. Analysis of the genome structure of the nonpathogenic probiotic Escherichia coli strain Nissle 1917[J]. J Bacteriol, 2004, 186(16):5432-5441.
[1] 刘思锐, 赵辰阳, 张睿, 张一休, 杨萌. 多普勒超声对孕鼠子宫动脉不同节段血流动力学参数的评估[J/OL]. 中华医学超声杂志(电子版), 2024, 21(09): 877-883.
[2] 史学兵, 谢迎东, 谢霓, 徐超丽, 杨斌, 孙帼. 声辐射力弹性成像对不可切除肝细胞癌门静脉癌栓患者放射治疗效果的评价[J/OL]. 中华医学超声杂志(电子版), 2024, 21(08): 778-784.
[3] 李华志, 曹广, 刘殿刚, 张雅静. 不同入路下行肝切除术治疗原发性肝细胞癌的临床对比[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 52-55.
[4] 陈浩, 王萌. 胃印戒细胞癌的临床病理特征及治疗选择的研究进展[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 108-111.
[5] 梁孟杰, 朱欢欢, 王行舟, 江航, 艾世超, 孙锋, 宋鹏, 王萌, 刘颂, 夏雪峰, 杜峻峰, 傅双, 陆晓峰, 沈晓菲, 管文贤. 联合免疫治疗的胃癌转化治疗患者预后及术后并发症分析[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 619-623.
[6] 张志兆, 王睿, 郜苹苹, 王成方, 王成, 齐晓伟. DNMT3B与乳腺癌预后的关系及其生物学机制[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 624-629.
[7] 刘柏隆, 周祥福. 压力性尿失禁阶梯治疗的项目介绍[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2025, 19(01): 125-125.
[8] 刘柏隆. 女性压力性尿失禁阶梯治疗之手术治疗方案选择[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2025, 19(01): 126-126.
[9] 马东扬, 李斌, 陆安清, 王光华, 雷文章, 宋应寒. Gilbert 与单层补片腹膜前疝修补术疗效的随机对照研究[J/OL]. 中华疝和腹壁外科杂志(电子版), 2024, 18(06): 629-633.
[10] 中华医学会器官移植学分会. 肝移植术后缺血性胆道病变诊断与治疗中国实践指南[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 739-748.
[11] 陈伟杰, 何小东. 胆囊癌免疫靶向治疗进展[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 763-768.
[12] 王国强, 张纲, 唐建坡, 张玉国, 杨永江. LINC00839 调节miR-17-5p/WEE1 轴对结直肠癌细胞增殖、凋亡和迁移的影响[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(06): 491-499.
[13] 崔军威, 蔡华丽, 胡艺冰, 胡慧. 亚甲蓝联合金属定位夹及定位钩针标记在乳腺癌辅助化疗后评估腋窝转移淋巴结的临床应用价值探究[J/OL]. 中华临床医师杂志(电子版), 2024, 18(07): 625-632.
[14] 王誉英, 刘世伟, 王睿, 曾娅玲, 涂禧慧, 张蒲蓉. 老年乳腺癌新辅助治疗病理完全缓解的预测因素分析[J/OL]. 中华临床医师杂志(电子版), 2024, 18(07): 641-646.
[15] 王帅, 张志远, 苏雨晴, 李雯雯, 王守凯, 刘琦, 李文涛. 孟德尔随机化及其在乳腺癌研究中的应用进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(07): 671-676.
阅读次数
全文


摘要